Q1 FY2027 · ended Sep 30, 2026 · Revenue $386.77M, +6.3% YoY · Filed Nov 4, 2026
Phibro Animal Health Corporation (PAHC) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q1 of fiscal 2027, the quarter ended Sep 30, 2026, it reported revenue of $386.8 million and net income of $29.5 million. Free cash flow was $7.3 million. As of Sep 30, 2026 it held $83.1 million in cash and investments and $665.1 million in total debt.
Revenue
$386.77M
+6.3% vs year-ago quarter
Net income
$29.52M
+11.3% vs year-ago quarter
Operating cash flow
$26.08M
+180.4% vs year-ago quarter
Free cash flow
$7.30M
+262.1% vs year-ago quarter
EPS
$0.72
+10.8% vs year-ago quarter
Dividend per share
$0.12
+0.0% vs year-ago quarter
Shares outstanding
68.91M
+126.2% vs prior quarter
Net cash
$-582.00M
Q1 FY2027
Operating margin
12.5%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PAHC (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Teaneck, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1069899
- Former names
- PHILIPP BROTHERS CHEMICALS INC (until May 14, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2027 Sep 30, 2026 |
Q4 FY2026 Jun 30, 2026 |
Q3 FY2026 Mar 31, 2026 |
Q2 FY2026 Dec 31, 2025 |
Q1 FY2026 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $386.8M | $396.7M | $383.5M | $373.9M | $363.9M |
| Operating income | $49.6M | $48.2M | $44.7M | $50.3M | $51.3M |
| Net income | $29.5M | $21.7M | $24.0M | $27.5M | $26.5M |
| Diluted EPS | $0.72 | $0.53 | $0.59 | $0.67 | $0.65 |
| Operating cash flow | $26.1M | $24.1M | $16.2M | $19.4M | $9.3M |
| Free cash flow | $7.3M | $5.2M | $890,000 | $8.3M | -$4.5M |
| Total assets | $1.5B | $1.5B | $1.4B | $1.4B | $1.4B |
| Total liabilities | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B |
| Stockholders' equity | $417.7M | $385.5M | $361.8M | $332.4M | $311.7M |
| Cash and investments | $83.1M | $82.0M | $77.5M | $74.5M | $85.3M |
| Total debt | $665.1M | $56.0M | $672.4M | $666.2M | $670.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Shareholder vote results
|
Nov 4, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Nov 3, 2026 | Nov 3, 2026 |
| ARS | Annual report to shareholders | Sep 18, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 26, 2026 | Aug 26, 2026 |
| 10-K | Annual report | Aug 26, 2026 | Jun 30, 2026 |
All 774 Phibro Animal Health Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.